PIK-108 is a non-ATP competitive, allosteric p110β/p110δ selective inhibitor[1].
PIK-108 is a non-ATP competitive, allosteric p110β/p110δ selective inhibitor[1].
PIK-108 (0.1-10 μM; 1 hour) blocks phosphorylation of PKB/Akt[1].
[1]. Zachary A Knight, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125(4):733-47. [2]. Jack S Chen, et al. Characterization of structurally distinct, isoform-selective phosphoinositide 3’-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Mol Cancer Ther. 2008 Apr;7(4):841-50.